About Chiasma
Chiasma is a company based in Needham (United States) founded in 2001 was acquired by Amryt Pharma in May 2021. Chiasma operates in a competitive market with competitors including Ultragenyx, Alnylam, Gemini Therapeutics, BioMarin Pharmaceutical and Mirum Pharmaceuticals, among others.
- Headquarter Needham, United States
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
$10 M (USD), Debt – Conventional
Jun 11, 2011
- Investors
-
Employee Count
Not available
-
Acquired by
Amryt Pharma
(May 04, 2021)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Chiasma
Investors in Chiasma
Chiasma has secured backing from 1 investor. Prominent investors backing the company include Amryt Pharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Therapeutics for rare dermatological and orphan diseases are developed.
|
Locked | Locked | Locked |
Investor details for Chiasma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Chiasma
Investment portfolio details for Chiasma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Chiasma
Detailed financials for Chiasma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Chiasma Comparisons
Peer comparison for Chiasma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Chiasma
Chiasma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Ultragenyx, Alnylam, Gemini Therapeutics, BioMarin Pharmaceutical and Mirum Pharmaceuticals, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
Developer of precision therapeutics for dry AMD and rare genetic diseases
|
|
| Locked | Locked | Locked |
Therapeutics for rare genetic diseases are developed by BioMarin Pharmaceutical.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics are developed for rare diseases treatment.
|
|
| Locked | Locked | Locked |
Developer of gene therapies for rare genetic diseases
|
Detailed competitors of Chiasma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Chiasma
Complete news archive for Chiasma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Chiasma
Chiasma was founded in 2001 and raised its 1st funding round 10 years after it was founded.
Chiasma is headquartered in Needham, United States. It is registered at Needham, Massachusetts, United States.
Raj Kannan is the current CEO of Chiasma.
Founded in 2001 and headquartered in Needham, United States, operations are focused on the biotechnology sector. Therapies for rare and debilitating diseases are advanced through the proprietary Transient Permeability Enhancer (TPE) platform, enabling oral formulations of medications traditionally administered by injection. The lead candidate, Mycapssa (octreotide capsules), targets acromegaly and has progressed to phase III clinical trials, with company products receiving FDA approval.
Chiasma's top competitors include Alnylam, BioMarin Pharmaceutical and Pharvaris.
Chiasma has 1 investor. Key investors include Amryt Pharma.